Unfortunately, the treatment of breast cancer is not without its consequences. Chemotherapy and adjuvant therapy to remove cancerous tissue can result in deficits in attention, speed of processing, memory, and quality of life. While past studies have identified memory and executive function as valuable, important determinants of long-term survival and quality of life in survivors of different types of cancer, it is unclear if standard care methods alone prove successful in attenuating declines in these variables. Previous research in breast cancer populations has found that executive function difficulties, namely in working memory, cognitive flexibility, and processing speed, as well as fatigue, are the most commonly described deficits. Furthermore, evidence suggests impairments in cognitive functioning may persist in up to 35% of breast cancer survivors years after treatment ends.